Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)

News provided by

Research and Markets

17 Nov, 2014, 17:32 GMT

Dublin, Nov. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Diagnostic Markets for Women's Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The women's health arena, both therapeutics and diagnostics, has grown considerably as a specialty medical field. Once limited to obstetrics and gynecology, it now includes other fields, such as urology, maternal-fetal medicine, as well as autoimmune disease and cystic fibrosis. At many clinics and practices focused on the health of women, a range of specialties are offered, which often results in a need for specific types of women's health-related testing. Generally, and from a perspective on women's health, diagnostics are playing an ever increasing role.

Worldwide, women are living longer than men. There is a need to improve the understanding of the differences, in terms of health, between the sexes and to translate that knowledge into improved medical diagnostics, practice and therapies.

Kalorama Information's Women's Health Diagnostic Markets analyzes the current and potential world markets for key diagnostic tests targeted at women's health. This report generally forecasts future market growth for these tests to 2018. Market segments covered include the US, Europe, China, Brazil, Japan and rest of world markets.

The report presents market developments in women's health diagnostics, including in-depth analysis of the following testing fields:

  • Pregnancy and Ovulation Testing
  • Bone Density Testing
  • Prenatal Screening
  • Ultrasound
  • Mammography
  • Pap Smears
  • Colposcopy
  • HPV Testing
  • Ovarian Cancer Testing
  • Urinary Tract Infections
  • Neonatal Jaundice
  • Autoimmune Disease
  • Cystic Fibrosis

Over the next few decades, comprehensive genomics-based health care should be the norm in the US and much of Europe. In the next decade, genetic tests will routinely predict individual susceptibility to disease. Diagnoses of many conditions will be much more thorough and specific than now. The report gives insight into understanding the molecular basis of disease.

Women's Health Diagnostic Markets also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include:

  • GE Healthcare
  • GenMark Diagnostics
  • Hologic
  • Immco Diagnostics
  • Luminex
  • Nova Biomedical
  • Philips Healthcare
  • Siemens Healthcare
  • Somagen Diagnostics

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data are generated into multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.

Key Topics Covered:

1.0 Executive Summary

2.0 Introduction

3.0 Market Developments in Women's Health Diagnostics

4.0 Pregnancy and Ovulation

5.0 Bone Density Testing

6.0 Prenatal Screening

7.0 Ultrasound

8.0 Mammography

9.0 Pap Smears

10.0 Colposcopy

11.0 HPV Testing

12.0 Ovarian Cancer

13.0 Urinary Tract Infections

14.0 Neonatal Jaundice

15.0 Autoimmune Disease

16.0 Cystic Fibrosis

For more information visit http://www.researchandmarkets.com/research/5bw9dm/diagnostic

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com